Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Prevalence of cardiovascular risk and atherosclerotic cardiovascular disease in people with type 2 diabetes in the United Arab Emirates: Results from the prevalence of atherosclerotic cardiovascular disease in patients with type 2 diabetes across Middle East and African countries (PACT-MEA) study","authors":"Fatheya Al. Awadi ,&nbsp;Fauzia Rashid ,&nbsp;Ghada Awada ,&nbsp;Haitham Seifeldin ,&nbsp;Hani Sabbour ,&nbsp;Hazem Aly ,&nbsp;Jalal Nafach ,&nbsp;Khadija Hafidh ,&nbsp;Loai Abudaqa ,&nbsp;Mahir K. Jallo ,&nbsp;Wael Almahmeed ,&nbsp;Zufana Nazir","doi":"10.1016/j.dsx.2025.103224","DOIUrl":"10.1016/j.dsx.2025.103224","url":null,"abstract":"<div><h3>Aim</h3><div>Atherosclerotic cardiovascular disease (ASCVD) is a significant cause of morbidity and mortality in type-2 diabetes mellitus (T2D) patients. This subset analysis of the PACT-MEA study compares T2D data from the UAE with data from other Middle Eastern and African (MEA) countries.</div></div><div><h3>Methods</h3><div>Data were extracted from the participants' medical charts from March 2022 to August 2022 across nine centers in the UAE (n = 542). The prevalence and 10-year CVD risk estimates were evaluated and categorized according to European Society of Cardiology (ESC) 2021 guidelines and compared between MEA (regional) and UAE populations.</div></div><div><h3>Results</h3><div>Participants with T2D from the UAE, enrolled in secondary care, had a median age of 55.7 years. The estimated 10-year CVD risk was 99.8 % in the UAE and 99.3 % in the MEA. Established ASCVD prevalence (eASCVD) was 29.7 % in the UAE and 20.9 % in the MEA. Coronary artery disease was the most common ASCVD type (95.0 %).</div></div><div><h3>Conclusion</h3><div>Nearly one-third of T2D patients had eASCVD in UAE, compared to one-fifth in MEA. Most participants were at high or very high risk for ASCVD, but none met all ESC 2021 guidelines, highlighting the need for developing regional strategies to reduce ASCVD risk.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 4","pages":"Article 103224"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative assessment of metabolic memory and its prediction of renal function decline in patients with type 2 diabetes: A retrospective observational study","authors":"Kentaro Oniki ,&nbsp;Takuro Shigaki ,&nbsp;Ayami Kajiwara-Morita ,&nbsp;Keiichi Shigetome ,&nbsp;Akira Yoshida ,&nbsp;Hideaki Jinnouchi ,&nbsp;Junji Saruwatari","doi":"10.1016/j.dsx.2025.103225","DOIUrl":"10.1016/j.dsx.2025.103225","url":null,"abstract":"<div><h3>Aims</h3><div>This study quantitatively assesses metabolic memory by modeling the relationship between hyperglycemic exposure and renal function decline in patients with type 2 diabetes (T2D).</div></div><div><h3>Methods</h3><div>This retrospective longitudinal study included 381 Japanese patients with T2D. Hyperglycemic exposure was presented by calculating the area under the curve (AUC) for HbA1c ≥ 6 % (AUC_{HbA1c ≥ 6 %}) during the observation period. A non-linear mixed-effects model was constructed to predict changes in estimated glomerular filtration rate (eGFR) based on AUC_{HbA1c ≥ 6 %}.</div></div><div><h3>Results</h3><div>The relationship between AUC_{HbA1c ≥ 6 %} and eGFR changes was shown by a sigmoidal curve, with sex, age, diabetic retinopathy, dyslipidemia, and hypertension incorporated as covariates. The predictive utility of the model was validated using goodness-of-fit plot, visual predictive check, and bootstrap methods.</div></div><div><h3>Conclusions</h3><div>We developed an AUC_{HbA1c ≥ 6 %}-based model to predict renal function decline in patients with T2D, showing that AUC_{HbA1c ≥ 6 %} may serve as a quantitative indicator of metabolic memory.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 4","pages":"Article 103225"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rational application of weight loss therapies according to new obesity guidelines in Asian Indians: A perspective for low-income settings","authors":"Anoop Misra","doi":"10.1016/j.dsx.2025.103226","DOIUrl":"10.1016/j.dsx.2025.103226","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 4","pages":"Article 103226"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143879142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the current issue","authors":"Ningjian Wang ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2025.103229","DOIUrl":"10.1016/j.dsx.2025.103229","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103229"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collaborative innovations in diabetes self-care for individuals with type 2 diabetes and schizophrenia: A Participatory Design study developing a diagnosis-specific educational manual","authors":"Tanja Juhl Mikkelsen ,&nbsp;Dorte Moeller Jensen ,&nbsp;Elsebeth Stenager ,&nbsp;Mette Juel Rothmann","doi":"10.1016/j.dsx.2025.103220","DOIUrl":"10.1016/j.dsx.2025.103220","url":null,"abstract":"<div><h3>Background and aims</h3><div>Individuals with schizophrenia are at high risk of developing type 2 diabetes. This study aimed to develop a tailored solution to address their complex diabetes care needs, based on insights from patients and healthcare professionals, to enhance self-care.</div></div><div><h3>Methods</h3><div>Using a Participatory Design approach, we conducted three workshops and an evaluation, which included focus groups, interviews, and written feedback. Patients, healthcare professionals, and stakeholders actively participated in all stages of the process between May 2022 and December 2023. Iterative processes ensured comprehensive input in idea generation and concept development. Data analysis followed the steps of planning, acting, observing, and reflecting. The study is reported using SRQR framework.</div></div><div><h3>Results</h3><div>Participants highlighted challenges such as navigating a fragmented healthcare system, undertreatment, and stigma. In response, a tailored educational manual for voluntary mentors was developed. This two-day training program equips mentors to support individuals with type 2 diabetes and schizophrenia, fostering collaboration and bridging the gap between psychiatric and somatic care.</div></div><div><h3>Conclusions</h3><div>A co-designed approach may enhance diabetes self-care and improve coordination between healthcare sectors.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103220"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variation in targets of antihyperglycemic drugs and inflammatory bowel disease’ risk: A mendelian randomization study","authors":"Jiaxi Zhao ,&nbsp;Rong Chen ,&nbsp;Mengqi Luo ,&nbsp;Quanjing Zhu ,&nbsp;Qian Zhao","doi":"10.1016/j.dsx.2025.103204","DOIUrl":"10.1016/j.dsx.2025.103204","url":null,"abstract":"<div><h3>Aim</h3><div>Antihyperglycemic drugs have potential therapeutic benefits for inflammatory bowel disease (IBD). We aimed to investigate the association between genetic variations in gene-targeted antihyperglycemic drugs and the risk of IBD.</div></div><div><h3>Methods</h3><div>Summary statistics for HbA1c data were from the UK Biobank including 344,182 participants. Statistics of IBD were obtained from UK Inflammatory Bowel Disease Genetics. Two Mendelian randomization methods were employed to derive the main findings.</div></div><div><h3>Results</h3><div>In the SMR analysis, increased expression of genetic variations in SGLT2 inhibitor targets (gene: SLC5A2) was linked to a higher risk of CD (OR: 1.97, <em>P</em> = 0.048). Genetic variation in brain cerebellum tissue of sulfonylurea targets (gene: ABCC8) expression was positively associated with IBD (OR = 1.11, <em>P</em> = 0.000). The genetic variation in the GLP-1RA targets (gene: GLP1R) expression was positively correlated with IBD (OR: 1.45, <em>P</em> = 0.039). The IVW-MR analysis suggested reduced IBD and CD risk with expression of increased genetic variation in the thiazolidinediones targets (gene: PPARG).</div></div><div><h3>Conclusion</h3><div>Genetic variations in SGLT2 inhibitor targets might be associated with an increased risk of CD. The ABCC8 gene might be linked to IBD, CD, and UC. There might be a positive correlation between genetic variation in the GLP-1RA targets expression and IBD occurrence.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103204"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143519111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes","authors":"Anoop Misra ,&nbsp;Ashish Kumar ,&nbsp;Mohammad Shafi Kuchay ,&nbsp;Amerta Ghosh ,&nbsp;Seema Gulati ,&nbsp;Narendra Singh Choudhary ,&nbsp;Deep Dutta ,&nbsp;Praveen Sharma ,&nbsp;Naval K. Vikram","doi":"10.1016/j.dsx.2025.103209","DOIUrl":"10.1016/j.dsx.2025.103209","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103209"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal serum folate status during early pregnancy: Sex-specific association with neonatal adiposity","authors":"Nishanthi Periyathambi ,&nbsp;Nithya Sukumar ,&nbsp;Yonas Ghebremichael-Weldeselassie ,&nbsp;Antonysunil Adaikalakoteswari ,&nbsp;Chittaranjan Yajnik ,&nbsp;Caroline Fall ,&nbsp;Ponnusamy Saravanan","doi":"10.1016/j.dsx.2025.103222","DOIUrl":"10.1016/j.dsx.2025.103222","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Early pregnancy folate has been associated with GDM and possible adiposity in the newborn. The present study examined associations between maternal early pregnancy folate levels and sex-specific neonatal anthropometry. We further explored possible mediation by maternal glycemia on the association between folate and neonatal adiposity.</div></div><div><h3>Methods</h3><div>Sub-group data (<em>n</em> = 511) from a UK multi-ethnic early pregnancy longitudinal study (micronutrients in Pregnancy as a Risk factor for gestational Diabetes and Effects on mother and baby; PRiDE) was used. Maternal serum folate was assessed during early pregnancy (Mean ± SD = 12.5 ± 1.6 gestational weeks) and infant anthropometry including skinfold thickness (SFT) and mid-upper arm circumference (MUAC) at birth. Multiple linear regression was performed to analyse the relationship between maternal folate and infant adiposity indices. Interaction analysis was used to identify maternal glucose mediation of this relationship.</div></div><div><h3>Results</h3><div>Excess folate levels (≥45 nmol/l) were found in 40.3 % pregnant women (<em>n</em> = 206). Early pregnancy folate (1 SD unit) was positively associated with male newborn triceps SFT (std β = 0.17 (95 % CI: 0.06, 0.29; <em>p &lt;</em> 0.05)) after adjusting for key maternal and infant confounders in multiple comparisons using Benjamini-Hochberg procedure. However, no associations were seen in female newborns. No influence of maternal fasting (FPG) and 2-h plasma glucose (2 h-PG) were detected on the association between folate and newborn anthropometry.</div></div><div><h3>Conclusion</h3><div>Our findings suggest a potential sex-specific influence of maternal folate on infant anthropometric indices. The association between early pregnancy folate on newborn adiposity was not mediated by maternal FPG and/or 2 h-PG at 24–28 weeks.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103222"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5–15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials","authors":"Akriti Singh ,&nbsp;Awadhesh Kumar Singh ,&nbsp;Ritu Singh ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2025.103212","DOIUrl":"10.1016/j.dsx.2025.103212","url":null,"abstract":"<div><h3>Background and aims</h3><div>Both semaglutide 2.4 mg and tirzepatide have been recently approved for chronic use in obesity. There is a lack of literature comparing the efficacy and safety of both these agents in people with obesity/overweight with or without type 2 diabetes (T2D). We systematically reviewed Phase 3 randomized controlled trials (RCTs) conducted with two agents to synthesize the comparative efficacy and safety outcomes.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed electronic databases until December 15, 2024, using selected keywords and Boolean “AND.” Subsequently, we compared the most closely matched trials conducted with semaglutide 2.4 mg and tirzepatide through an adjusted (if baseline imbalance in treatment outcome modifiers present) or unadjusted (in the absence of baseline imbalance) indirect treatment comparison method.</div></div><div><h3>Results</h3><div>We identified one trial each of semaglutide 2.4 mg (STEP-1) and tirzepatide 5, 10, and 15 mg (SURMOUNT-1) in obese or overweight people without T2D and one trial each of semaglutide 2.4 mg (STEP-2) and tirzepatide 10 and 15 mg (SURMOUNT-2) in overweight people with T2D that were almost entirely comparable concerning baseline outcome modifier characteristics. Our unadjusted analysis without individual patients' data found relatively higher (4 and 5.4 % additional) weight loss, HbA1c (−0.4 % additional) reduction, and fewer gastrointestinal side effects (GI S/E) with tirzepatide 10 and 15 mg, respectively, than with semaglutide 2.4 mg, in the intention-to-treat analysis.</div></div><div><h3>Conclusion</h3><div>Tirzepatide 10 and 15 mg are more effective and have fewer GI S/E than semaglutide 2.4 mg. A well-powered head-to-head RCT is currently needed to confirm these findings.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103212"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How can we best support insulin self-titration in type 2 diabetes patients: A systematic review and network meta-analysis","authors":"Panitan Pitak ,&nbsp;Kansak Boonpattharatthiti ,&nbsp;Anjana Fuangchan ,&nbsp;Ines Krass ,&nbsp;Teerapon Dhippayom","doi":"10.1016/j.dsx.2025.103221","DOIUrl":"10.1016/j.dsx.2025.103221","url":null,"abstract":"<div><h3>Introduction</h3><div>The efficacy of insulin self-titration in type 2 diabetes (T2D) varies by support strategy. This study aimed to identify the effects of different insulin self-titration support strategies in patients with T2D.</div></div><div><h3>Methods</h3><div>PubMed, EMBASE, CENTRAL, and EBSCO Open Dissertations were searched from inception to January 2023. Randomized controlled trials (RCTs) on T2D patients that reported HbA1c reduction of insulin self-titration supports were included. The interventions were classified based on the following components: dosage guidance (DG), non-dosage guidance (NDG) and empowerment. The pooled estimates were presented as mean differences (MDs) and risk ratios (RRs) with 95 % confidence interval (CI) using a random-effects model. The certainty of evidence was evaluated utilizing the CINeMA online platform.</div></div><div><h3>Results</h3><div>Seventeen RCTs (13,528 participants) were included. Compared with usual care (UC), the greatest reduction in HbA1c was observed in patients receiving dosage guidance/Empowerment (MD −1.20; 95 %CI: −2.33,−0.07), with moderate certainty of evidence. Lesser HbA1c reduction, MD [95 % CI], were observed in other support strategies when compared with usual care as follows: −0.97 [−1.24,−0.69] in non-dosage guidance/Empowerment, −0.42 [−0.60,−0.24] in dosage guidance, and −0.31 [−0.58,−0.03] in non-dosage guidance. The risk of severe hypoglycemia was not significantly difference among all support strategies, with very low certainty.</div></div><div><h3>Conclusions</h3><div>Incorporating patient empowerment into insulin self-titration support strategy, either dosage or non-dosage guidance, is more effective in lowering HbA1c.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103221"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}